◎ Sugi Atlas

Atlas / Drug / Fluocinonide

Fluocinonide

drug
On this page

Also known as FluocinolideFluocinonidaFluocinonide emulsified baseLidexLidex-eMetosynMetosyn fapgNSC-101791VanosSID855724SID170464717SID144203989FLUOCINONIDE (VANOS)C0164469

Summary

Fluocinonide (CHEMBL1501) is an approved small molecule (ATC C05AA11) targeting NR3C1; indicated across 5 conditions including skin disorder and hemorrhoid.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: C05AA11 (+1 more)
  • Targets: 1 (NR3C1)
  • Indications: 5 conditions
  • Clinical trials: 8
  • Chemistry: 494.5 Da · C26H32F2O7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1501
NameFluocinonide
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID9642
ATCC05AA11, D07AC08
Molecular formulaC26H32F2O7
Molecular weight494.5
InChIKeyWJOHZNCJWYWUJD-IUGZLZTKSA-N

SMILES: CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C

IUPAC name: [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate

Also known as: Fluocinolide, Fluocinonida, Fluocinonide, Fluocinonide emulsified base, Lidex, Lidex-e, Metosyn, Metosyn fapg, NSC-101791, Vanos, fluocinonide, SID855724

Patent coverage: 7,387 distinct patent families (26,931 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorAgonist8.280.9%P04150

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Androgen receptor, Glucocorticoid receptor, Progesterone receptor, Aldehyde dehydrogenase 1A1, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
HIF1A9Potency1nMCHEMBL_ACT_4129041
HIF1A9Potency1nMCHEMBL_ACT_4520863
NR3C18.62Ki2.39nMCHEMBL_ACT_7648590
NR3C18.28IC505.26nMCHEMBL_ACT_7648589
PGR7.7AC5020.2nMCHEMBL_ACT_25204629
AR6.2AC50627.1nMCHEMBL_ACT_25203696

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
skin disorder4MONDO:0005093EFO:0000701
hemorrhoid4MONDO:0004872EFO:0009552
breast carcinoma2MONDO:0004989EFO:0000305
atopic eczema2MONDO:0004980EFO:0000274
psoriasis0MONDO:0005083EFO:0000676

Clinical trials

Total trials: 8.

Phase distribution

PhaseTrials
PHASE23
Not specified2
PHASE41
EARLY_PHASE11
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00819507PHASE4COMPLETEDVANOS Cream and Skin Barrier Function
NCT00667589PHASE2TERMINATEDSorafenib-induced Hand- Foot Skin Reaction Treatment
NCT01422408PHASE2COMPLETEDFluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
NCT01469767PHASE2COMPLETEDEfficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
NCT06504160PHASE1RECRUITINGTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
NCT01802580EARLY_PHASE1COMPLETEDUsing an Internet Study to Improve Adherence for Psoriasis Patients
NCT02176148Not specifiedCOMPLETEDCutaneous Lupus Medication Experience Study
NCT06135805Not specifiedCOMPLETEDImpact of Fluocinonide 0,05% in Oral Lichen Planus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot